The 17 references in paper A. Grigoryeva V., M. Dorofeeva Yu., V. Perminov S., E. Belousova D., А. Григорьева В., М. Дорофеева Ю., В. Перминов С., Е. Белоусова Д. (2018) “Анализ эффективности антиэпилептических препаратов в лечении инфантильных спазмов и фокальной эпилепсии, ассоциированной с туберозным склерозом // Analysis of the efficacy of antiepileptic drugs in the treatment of infantile spasms and focal epilepsy associated with tuberous sclerosis complex” / spz:neicon:rjdn:y:2018:i:3:p:36-44

1
Белоусова Е.Д., Дорофеева М.Ю., Пивоварова А.М., Катышева О.В. Диагностика туберозного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(5):46–51. [Belousiva E.D. Dorofeeva M.Yu., Pivovarova A.M., Katysheva O.V. Diagnosis of tuberous sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(5):46–51. (In Russ.)].
(check this in PDF content)
2
Curatolo P., Jóźwiak S., Nabbout R., TSC Consensus Meeting for SEGA and Epilepsy Management. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol 2012;16(6):582–6. PMID: 22695035. DOI: 10.1016/j.ejpn.2012.05.004.
(check this in PDF content)
3
Curatolo P., Moavero R., de Vries P.J. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015;14(7):733–45. PMID: 26067126. DOI: 10.1016/S14744422(15)00069-1.
(check this in PDF content)
4
Cusmai R., Moavero R., Bombardieri R. et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav 2011;22(4):735–9. PMID: 22142783. DOI: 10.1016/j.yebeh.2011.08.037.
(check this in PDF content)
5
Fallah A., Guyatt G.H., Snead O.C. et al. Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: An Individual Participant Data Meta-Analysis. PLoS One 2013;8(2):e53565. PMID: 23405072. DOI: 10.1371/journal.pone.0053565.
(check this in PDF content)
6
Fallah A., Weil A.G., Wang S. et al. Costutility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex. Epilepsy Behav 2016;63:79–88. PMID: 27591681. DOI: 10.1016/j.yebeh.2016.07.034.
(check this in PDF content)
7
Epileptic spasms. Available at: https:// www.epilepsydiagnosis.org/seizure/epileptic-spasms-overview.html.
(check this in PDF content)
8
Jeong A., Nakagawa J.A., Wong M. Predictors of drug resistant epilepsy in tuberous sclerosis complex. J Child Neurol 2017;32(14):1092–8. PMID: 29129154. DOI: 10.1177/0883073817737446.
(check this in PDF content)
9
Krueger D.A., Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013;49(4):255–26. PMID: 24053983. DOI: 10.1016/j.pediatrneurol.2013.08.002.
(check this in PDF content)
10
Lux A.L., Osborne J.P. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004;45(11):1416–28. PMID: 15509243. DOI: 10.1111/j.0013-9580.2004.02404.x.
(check this in PDF content)
11
Major P., Thiele E.A. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav 2008;13(2):357–60. PMID: 18468492. DOI: 10.1016/j.yebeh.2008.04.001.
(check this in PDF content)
12
Northrup H., Krueger D.A. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 2013;49(4):243–54.
(check this in PDF content)
13
Overwater I.E., Bindels-de Heus K., Rietman A.B. et al. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Epilepsia 2015;56(8):1239–45. DOI: 10.1111/epi.13050.
(check this in PDF content)
14
Roach E.S., Di Mario F.J., Kandt R.S., Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. J Child Neur 1999;14(6):401–7. DOI: 10.1177/088307389901400610.
(check this in PDF content)
15
Saxena A., Sampson J.R. Epilepsy in tuberous sclerosis: phenotypes, mechanisms, and treatments. Semin Neurol 2015;35(3):269–76. DOI: 10.1055/s-0035-1552616.
(check this in PDF content)
16
Scheffer I.E., Berkovic S., Capovilla G. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–21. DOI: 10.1111/ epi.13709.
(check this in PDF content)
17
Zhang B., McDaniel S.S., Rensing N.R., Wong M. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One 2013;8(2);e57
(check this in PDF content)